WebMD3d
FDA Approves Drug for Aggressive Small-Cell Lung Cancer
The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...
Cancer Therapy Advisor6d
Imfinzi Approved as Consolidation in LS-SCLC
The FDA has approved Imfinzi (durvalumab) to treat LS-SCLC that has not progressed after concurrent platinum-based chemotherapy and radiation.
pharmaphorum7d
FDA clears AZ's Imfinzi for aggressive lung cancer
Imfinzi is already approved for extensive-stage SCLC based on the results of the CASPIAN trial, as well as for locally ...
AstraZeneca’s Imfinzi approved in U.S. as immunotherapy regimen for LS-SCLC
Imfinzi has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer, LS-SCLC ...
Medscape6d
FDA Approves Durvalumab for Limited-Stage SCLC
Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.
The Pharma Letter7d
Imfinzi first immunotherapy to win LS-SCLC nod
AstraZeneca’s Imfinzi (durvalumab) has been approved in the USA for the treatment of adults with limited-stage small cell ...
AstraZeneca: FDA Approves Imfinzi To Treat Adult Patients With Limited-stage Small Cell Lung Cancer
British drug maker AstraZeneca Plc (AZN.L, AZN) announced Thursday that the U.S. Food and Drug Administration has approved Imfinzi ...
FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody, Imfinzi (durvalumab), to ...
Nasdaq7d
AstraZeneca’s Imfinzi approved in U.S. as immunotherapy regimen for LS-SCLC
AstraZeneca’s (AZN) Imfinzi has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer, LS-SCLC whose disease has not progressed following ...